CytomX Therapeutics, Inc. (NASDAQ:CTMX) is reporting third quarter financial results on Thursday 5th November 2020, after market close.
According to analysts surveyed by Thomson Reuters, CTMX is expected to report 3Q20 loss of $ 0.48 per share from revenue of $ 16.34 million.
For the full year, analysts anticipate top line of $ 98.93 million, while looking forward to loss of $ 1.05 per share bottom line.
Previous Quarter Performance
CytomX Therapeutics, Inc. revealed loss for the second quarter of $ 0.34 per share, from the revenue of $ 16.61 million. Wall street analysts are predicting, CTMX to report 2Q20 income of $ 0.16 per share from revenue of $ 48.21 million. The bottom line results missed street analysts by $ 0.5 or 312.5 percent, at the same time, top line results fell short of analysts by $ 31.6 million or 65.55 percent.
Stock Performance
Shares of CytomX Therapeutics, Inc. traded up $ 0.34 or 5.05 percent on Wednesday, reaching $ 7.07 with volume of 455.00 thousand shares. CytomX Therapeutics, Inc. has traded high as $ 7.15 and has cracked $ 6.66 on the downward trend
The closing price of $ 7.07, representing a 86.94 % increase from the 52 week low of $ 3.60 and a 56.41 % decrease over the 52 week high of $ 15.44.
The company has a market capital of $ 326.58 million and is part of the Healthcare sector and Biotechnology industry.
Recent Analyst recommendations
- On 22nd September 2020, downgraded by Guggenheim to Neutral from Buy rating.
Conference Call
CytomX Therapeutics, Inc. will be hosting a conference call at 5:00 PM eastern time on 5th November 2020, to discuss its 3Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.cytomx.com
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops a novel class of investigational antibody therapeutics based on its Probody technology platform for the treatment of cancer.
